Carmat: 30 heart transplants passed

(CercleFinance.com) - Carmat announced on Wednesday that it had passed the milestone of 30 heart transplants after support with its Aeson artificial heart.


By the end of October, 30 patients had received a successful heart transplant after being on Aeson support, a procedure known as 'bridge to transplant'.

Of these 30 transplants carried out in seven countries, including 16 in France and five in Germany, 16 have been performed since the beginning of 2024, demonstrating a "clear" acceleration in the adoption of the device, according to Carmat.

On average, the 30 patients benefited from Aeson support for 156 days before transplantation, with the maximum period recorded being 308 days.

For the record, the Aeson artificial heart is CE-marked for the 'bridge to transplantation' indication, enabling it to be marketed in Europe for heart failure patients likely to benefit from a heart transplant within 180 days.

With the company due to host an event bringing together over 100 European experts at the end of the month, Carmat reports "strong interest" from the medical community in Aeson, with the aim of eventually obtaining the so-called "destination therapy" indication, which would enable patients to live sustainably on Aeson support, without subsequent transplantation.

Following these indications, Carmat shares rose by around 2.5% on Wednesday morning on the Paris Bourse.

Copyright (c) 2024 CercleFinance.com. All rights reserved.